Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: LaserSight Inc.

This article was originally published in The Gray Sheet

Executive Summary

LaserSight Inc.: Commences Phase IIb U.S. clinical trials of its PhotoScan 2000 excimer laser for photorefractive keratectomy (PRK). The 125-patient, five-site study includes patients with up to -10 diopters of nearsightedness, LaserSight says. Phase III trials of the PRK device are ongoing in Canada and Europe. The firm also is conducting Phase II trials in the U.S., Canada and Europe for photoastigmatic refractive keratectomy (PARK), designed to correct "myopic astigmatism up to 6.5 diopters in conjunction with the correction of myopia of up to -10.5 diopters"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel